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Louis Anthony Cox Jr.
Cox Associates, Denver, Colorado
Human cancer risks from benzene have been estimated from epidemiological data, with supporting
evidence from animal bioassay data. This article reexamines the animal-based risk assessments
using physiologically based pharmacokinetic (PBPK) models of benzene metabolism in animals
and humans. Internal doses (total benzene metabolites) from oral gavage experiments in mice are
well predicted by the PBPK model. Both the data and the PBPK model outputs are also well
described by a simple nonlinear (Michaelis-Menten) regression model, as previously used by Bailer
and Hoel [Metabolite-based internal doses used in risk assessment of benzene. Environ Health
Perspect 82:177-184 (1989)]. Refitting the multistage model family to internal doses changes
the maximum-likelihood estimate (MLE) dose-response curve for mice from linear-quadratic
to purely cubic, so that low-dose risk estimates are smaller than in previous risk assessments. In
contrast to Bailer and Hoel's findings using interspecies dose conversion, the use of internal dose
estimates for humans from a PBPK model reduces estimated human risks at low doses.
Sensitivity analyses suggest that the finding of a nonlinear MLE dose-response curve at low
doses is robust to changes in internal dose definitions and more consistent with epidemiological
data than earlier risk models. A Monte-Carlo uncertainty analysis based on maximum-entropy
probabilities and Bayesian conditioning is used to develop an entire probability distribution for the
true but unknown dose-response function. This allows the probability of a positive low-dose
slope to be quantified: it is about 10%. An upper 95% confidence limit on the low-dose slope of
excess risk is also obtained directly from the posterior distribution and is similar to previous q1*
values. This approach suggests that the excess risk due to benzene exposure may be
nonexistent (or even negative) at sufficiently low doses. Two types of biological information about
benzene effects-pharmacokinetic and hematotoxic-are examined to test the plausibility of
this finding. A framework for incorporating causally relevant biological information into benzene
risk assessment is introduced, and it is shown that both pharmacokinetic and hematotoxic models
appear to be consistent with the hypothesis that sufficiently low concentrations of inhaled
benzene do not create an excess risk. - Environ Health Perspect 104(Suppl 6):1413-1429 (1996)
Key words: biologically based risk assessment, dose-response modeling, Monte-Carlo
uncertainty analysis, simulation modeling, causal modeling
Introduction
For risk managers and public health
decision makers, the most important ques-
tions about human cancer risks from expo-
sures to low concentrations ofbenzene are
a) Is there any excess risk at low exposure
concentrations (e.g., below 1 ppm)? b) If
so, how large is the excess risk, and how
does it vary with changes in exposure
concentration and timing?
After more than 20 years of vigorous
investigation using increasingly sophisti-
cated techniques of molecular biology,
computer and statistical risk models, and
epidemiological data analyses, the answers
to these questions remain unknown. This
paper briefly reviews how inferences about
low-dose human cancer risks are tradition-
ally drawn from animal bioassay data. It
then suggests that a different approach is
needed for benzene because benzene biol-
ogy is inconsistent with the assumptions
embedded in the usual approach. Three
methods that may lead to more realistic
and informative estimates ofbenzene risks
are introduced as follows:
* Use ofMonte-Carlo uncertainty analysis
to quantify the probability distribution
ofthe entire dose-response function for
benzene-induced tumors in male
B6C3F1 mice. In contrast to previous
Monte-Carlo uncertainty analyses for
benzene that treat uncertain model
parameter values as random variables
(1), here the true response probabilities
in different experimental dose groups
are treated as random variables.
* Use of two species-specific physiologi-
cally based pharmacokinetic (PBPK)
models, one for mice and the other for
humans, to quantify internal dose-
response functions and to extrapolate
risks from mice to humans. This
approach leads to conclusions opposite
to those previously reached using a
PBPK model for mice and a traditional
allometric scaling (2) approach to
interspecies extrapolation.
* A modeling framework for incorporat-
ing additional biological knowledge-
about cytotoxicity, cell kinetics, and
genotoxicity, as well as the information
about pharmacokinetics and metabo-
lism contained in the PBPK model-
into benzene dose-response models.
The quantal bioassay data displayed in
Table 1 motivate and illustrate the meth-
ods developed. These data are for the most
sensitive species, strain, and sex found
among many animal bioassay studies
reviewed by Crump and Allen (3). They
have been referenced by the Occupational
Safety and Health Administration (OSHA)
(4) in its regulation ofbenzene.
Applied risk assessment attempts to
draw inferences from data sets such as that
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Table 1. Oral gavage data for B6C3F1 male mice.
x= Dose in mg/kg/day 0 25 50 100
benzene
n(x) = Number of animals 50 50 50 50
exposed
r(x) = Fraction of mice with 0 0.08 0.40 0.74
tumors (squ&rnous
cell carcinomas)
From Crump and Allen (3), Appendix B, reproduced by
the U.S. EPA (5).
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described in Table 1 to answer the follow-
ing types ofquestions about risk: a) What
is the excess risk at 25 mg/kg/day?
Although the observed risk is 0.08, this
observation contains sampling variability
and ignores the information in the other
data points. Additional analysis is needed
to obtain a more informative answer.
b) What is the excess risk in male mice
exposed to 1 mg/kg/day? Answering this
question requires extrapolation beyond the
range of the data, and therefore requires
some sort of risk model or assumptions.
c) What is the excess risk in humans
exposed via inhalation to 1 ppm for
45 years, starting at age 20? This type of
question is of most interest to risk man-
agers. However, it cannot be answered
purely on the basis ofstatistical analysis of
the data. Instead, modeling assumptions
are required to permit extrapolation across
species, route of administration, and dose
regimen. For applied work, it is essential to
understand how robust risk conclusions are
to plausible changes in the model assump-
tions. Ifslightly more realistic assumptions
lead to large changes in estimated risk,
which turns out to be the case for benzene,
then the uncertainty about risks may be
driven more by model uncertainty than by
data uncertainty. However, model uncer-
tainty is more difficult to quantify and
manage. It has often been disregarded in
regulatory risk assessments ofbenzene.
Traditional risk assessment, discussed
next, infers from the data in Table 1 that
there is a strong, positive dose-response
relation for benzene that extends even to
very low doses. However, traditional risk
assessment incorporates assumptions (e.g.,
that risk is determined by total adminis-
tered dose, or that effects of exposure on
cell proliferation and cytotoxicity may be
ignored) that may not be appropriate for
benzene. Reanalysis ofthe data in Table 1
using more flexible methods indicates that
there is no evidence for an increased risk at
low exposure levels.
Traditional Statistical Risk
Assessment of Benzene
A traditional regulatory risk assessment
proceeds as follows:
Step 1. A dose metric and a statistical
risk model are chosen to relate the admin-
istered dose history to tumor probability.
Step 2. The parameters of the risk
model are estimated from the available
experimental data, e.g., by choosing para-
meter values that maximize the likelihood
ofthe data.
Step 3. Uncertainty about the parame-
ters is quantified using statistical theory.
Uncertainty about the dose metric and the
statistical risk model formula are usually
either ignored or treated by making risk
estimates for several different choices of
dose metrics and models.
Step 4. Risks are interpolated among
dose levels and extrapolated beyond the
conditions ofthe experimental data based
on the chosen dose metric and risk model,
e.g., to new species and new time patterns
of dose administration. Specifically, the
dose metric establishes which administered
dose histories are considered to create equal
risks, while the risk model quantifies how
large these risks are.
These steps will now be illustrated for
the data in Table 1.
Step 1. SelectionofaDoseMetric
A dose metric converts any specified
detailed administered dose history (a time
sequence ofhourly or daily benzene intakes
over a period ofweeks to years) into a single
corresponding number called the "dose,"
typically plotted on the horizontal axis of
the dose-response curve. Any two histories
that are assigned the same number (dose)
by the dose metric are thereby assumed to
create the same risk, even if the time pat-
tern or route ofadministration is different,
and even ifdifferent species and strains are
involved. An example ofa dose metric that
has been applied to the data in Table 1 (5)
is mg-lifetimes ofbenzene per unit ofsur-
face area of the exposed animal. For any
dose history (e.g., 60 days ofexposure to 25
mg/kg/day), the corresponding dose num-
ber is obtained by calculating the total
quantity ofbenzene (e.g., 1500 mg), multi-
plying it by the fraction of life exposed
(e.g., 60 days/1000 days for a species and
strain that lives 1000 days on average), and
dividing by surface area (approximated as
the two-thirds power ofthe animal's body
weight). In the remainder ofthis article, x
will denote the dose variable defined by the
selected dose metric (e.g., mg-lifetimes per
unit surface area).
The most common choice of dose
metric for risk interpolation and extrapola-
tion within a single species, strain, and sex
is the area-under-curve (AUC) dose met-
ric, which assigns the same dose (and
hence the same risk) to any two dose his-
tories that have the same integrated total
dose (AUC for the administered dose
history). For example, risk models in
which equal ppm-hr of benzene or equal
mg/kg of benzene create equal predicted
risks independent of the detailed time
pattern of dose administration are using
AUC dose metrics.
Step 2. ParameterEstimationvia
MaximumLikelihood
Once a dose metric has been selected,
experimental data such as those in Table 1
can be plotted to obtain an empirical dose-
response function. A statistical model of
the dose-response relation is typically rep-
resented by a multivariate function (letters
in bold type indicate vectors).
p=f(x,q)
where
p = lifetime probability oftumor
x= dose (computed via the dose metric
selected in Step 1)
q = a vector ofmodel parameters
f= assumed model formula.
For example, the data in Table 1 might be
assumed to result from the familiar multi-
stage risk model, which has the form
f(x,q) =
1-exp[-(qo+q1x+q2x2+... +qkxk)],
where
q= (qo, ql,q2,.*-, qk)-
By varying q, the model dose-response
functionf(x,q) may be made to approxi-
mate the empirical dose-response func-
tions obtained by plotting the fraction of
animals with tumors against the dose, x.
The quality of the approximation is quan-
tified by a specific criterion, such as the
likelihood criterion, which quantifies the
likelihood of the empirical curve, as pre-
dicted from the model curve; or the mean
squared difference between the empirical
and model values. Then q may be selected
to optimize the selected criterion. This
provides an estimate of q based on the
observed experimental data, the assumed
model, and the selected dose metric.
As an example, the maximum-likeli-
hood estimate (MLE) of q for the multi-
stage model was computed for the data in
Table 1, assuming an AUC dose metric of
mg/kg/day of administered benzene. The
value of q that maximizes the likelihood
function was found via a numerical opti-
mization computer program assuming that
only parameter vectors satisfying the
constraint q. 0 are to be considered, as is
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traditional in regulatory risk assessment.
The MLE for q is
q*=(q, ql, q2)* =(O, 0.00145, 0.00013)
(MLE parameter estimate).
These parameter values maximize the like-
lihood function
L(q) = Pr(Data q)
=Fxf(x,q)n(x)r(x)[1-f(x, q)][1-r(x)]n(x),
where n(x)r(x) denotes the number ofani-
mals that developed tumors out ofthe n(x)
animals in dose group x. They correspond
to the MLE dose-response model
p*(x) = 1-exp[-(0.00145x+0.00013x2)]
(MLE risk model for mice).
This model implies that, at very low doses,
p*(x)=0.00145x
(MLE low-dose excess risk).
Step 3. UncertaintyAnalysis:
Calculatingq1*
The quality ofthe MLE is often judged by
uncertainty analysis. Traditionally, uncer-
taintv analysis is based on construction of
confidence intervals or joint confidence
regions for the model parameters. An
approximate confidence region for q may
be constructed from the mathematical sta-
tistics result that, under certain technical
regularity conditions, e.g., that L(q) is
thrice differentiable and that q* lies in the
interior of its feasible region, the distribu-
tion of minus twice the log-likelihood
ratio, namely
-2 log[L(q)/L(q*)],
asymptotically approaches a X2 distribution
with k degrees of freedom (6). This
asymptotic result can be used to construct
approximate upper confidence limits
(UCLs) for the true but unknown value of
q from the MLE estimate q*. In particular,
it can be used to estimate a 95% UCL for
each component of q in the multistage
model, including the linear term, ql. This
provides the theoretical basis for calculat-
ing ql* in programs such as GLOBAL and
TOXRISK. The same technique can be
used to estimate approximate confidence
bands for parameters in other risk models.
The qi* value calculated for the low-dose
slope ofthe multistage dose-response func-
tion for benzene is
qi* =0.00773 expected excess tumors
per mg/kg/day ofbenzene.
Equivalently, the estimated 95% upper
confidence limit (UCL) on excess riskat very
lowdoses is given bythe linear function
p(x) =0.00773x
(95% UCL on low-dose excess risk).
Step4. ExtrapolatingRiskfrom
Oral Gavage DataforMiceto
Inhalation Hazards for Humans
To extrapolate from the oral gavage data
for mice (Table 1) to risks posed by inhala-
tion of low levels of benzene in humans,
the U.S. Environmental Protection Agency
(U.S. EPA) (5) selected mg-lifetimes of
benzene per unit surface area as the equiva-
lent dose metric for extrapolating risks
across routes and species. They also used
ppm-hr as a dose metric for risk interpola-
tion and extrapolation within a species.
The MLE for risk in any new situation
(i.e., species, route, and/or time pattern of
dosing) based on a risk assessment model
f(x, q) and MLE parameter estimate q*
assessed in a different situation is given by
the risk extrapolation formula
p*(x')=f(x' q*)
where x' denotes the dose corresponding to
the new situation. For example, to estimate
from the data in Table 1 the risk to a
human male from occupational inhalation
exposure to benzene, one would first calcu-
late the "equivalent" mg/kg/day, x',
received by the worker (based on inhala-
tion rate, body weight, and so forth) and
then apply the dose-response formula
derived from the mouse data
p*(x') =I-exp[-(0.00145x'+0.00013x'2)].
Thus, the risk created in a mouse by expo-
sure to 1 mg/kg/daysof benzene for a frac-
tionfof its lifetime is assumed to be equal
to the risk created in a human by continu-
ous inhalation ofthe following concentra-
tion ofbenzene:
(20 m3 inhaled by humans/day)
(1/70 kg for a human)(3.19 mg of
benzene/m3 of air inhaled per ppm
of benzene in the inhaled air)
(l/f relative duration of lifetime
human exposure)(70 kg per human/
mouse weight in kg)i3.
Using this factor for interspecies and inter-
route dose extrapolation yielded a 95%
UCL unit risk estimate for humans of
0.119 excess tumors per ppm-life-
time ofexposure to benzene (extrap-
olated 95% UCL).
The corresponding MLE for human
risk due to inhalation of benzene was
0.0161 expected excess tumors per ppm-
lifetime ofexposure (5).
Critique of Traditional
Benzene Risk Assessment
and Need for a New Approach
The preceding benzene risk assessment has
three limitations.
First, the assumption of an AUC dose
metric for benzene is not realistic. Many
experiments have shown that different time
patterns of benzene dose administration
with the same AUC produce very different
profiles of benzene metabolites (2) and
very different hematotoxic effects (7). For
example, 150 ppm ofbenzene inhaled for
2 hr causes more than 7 times greater pro-
duction ofprephenylmercapturic acid (an
indicator ofbenzene metabolism) than 50
ppm of benzene inhaled for 6 hr (2).
Similarly, exposing male CD-1 mice via
inhalation to 10 ppm of benzene for
6 hr/day, 5 days/week for 10 weeks (3000
ppm-hr of exposure) has no detectable
impact on marrow cellularity or on colony-
forming unit, granulocyte-macrophage
(CFU-GM) stem cells in bone marrow,
but 100 ppm for 6 hr/day for 5 days (also
3000 ppm-hr of exposure) significantly
depresses marrow colony-forming unit,
spleen (CFU-S) and CFU-GM cells (7).
Even more strikingly, while male NMRI
mice continuously exposed to 21 ppm of
benzene via inhalation for about a week
show very significantly depressed marrow
cellularity (cells/tibia) and CFU-GM con-
tent per tibia, mice exposed to up to 14 ppm
for up to 8 weeks-a much larger AUC
dose-show no significant changes in bone
marrow cellularity or CFU-GM content
(8). Other AUC dose violations and anom-
alies, such as the fact that exposure for
3 days per week may have a larger impact
on erythropoiesis than exposure for 5 days
per week (9), have been documented for
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benzene metabolism, cytotoxicity, and
genotoxicity. In light ofthese findings, the
AUC dose metric cannot be considered
biologically realistic for benzene.
The second limitation is that the ql*
methodology may not produce predictively
useful results for benzene. Reasons include
the following: a) The regularity conditions
needed to establish the asymptotic result
may not hold. For example, the usual regu-
larity conditions require that the true para-
meter vector q should lie in the interior of
its set of possible values (so that the con-
straint q . 0 is not binding). Yet, the MLE
for qo is 0. b) Asymptotic convergence pro-
vides no guarantees for real data set. Indeed,
Monte-Carlo simulation shows that conver-
gence is poor for some realistic-size data sets,
while the nonnegativity constraints on
model coefficients may lead to multi-modal
distributions of q* values and to unstable
MLE estimates ofrisk (10). The asymptotic
X-square distribution does not always pro-
vide a useful approximation to the actual
distribution of q around its MLE estimate,
as evaluated by Monte-Carlo analysis.
c) Model uncertainty is ignored. The multi-
stage model does not accurately describe
some real data sets (11). This possibility is
ignored in analyses ofun, c tainty using the
qj* methodology. Yet, such model uncer-
tainty (e.g., about whether the chosen para-
metric family of risk models contains the
true dose-response relation) may overwhelm
uncertainty due to statistical sampling vari-
ability in determining total uncertainty
about model-based riskpredictions.
These limitations imply that the com-
puted value of qi* may contain very little
information about the true plausible upper
limit on the low-dose slope. A different
uncertainty analysis methodology is needed
to produce more useful results. Advances
in uncertainty analysis methods, includ-
ing the widespread use of Monte-Carlo
uncertainty analysis and other computer-
intensive statistical methods (12) now offer
practical approaches for improving on
earlier uncertainty analyses for benzene.
The third limitation on benzene risk
assessment is that the human riskpredictions
made by the traditional risk assessment
model based on animal data do not appear
to agree with epidemiological data. For
example, the preceding risk model predicts
that the risk to a human exposed to xppm-
years ofbenzene via inhalation should exceed
1-exp(-0.016x)
(extrapolated lower bound
dose-response model).
(This is a lower bound because higher
order terms are neglected.) Thus, a worker
exposed to an average of25 ppm-years per
year for 40 years should have a lifetime
tumor probability due to benzene exposure
ofat least
1-exp[-(0.016)x(-1000 ppm-years/
70 years perlifetime)] =0.20.
This prediction appears to be incompatible
with observed tumor rates in highly exposed
human populations. For example, Turkish
shoe and handbag workers exposed to an
average ofover 1000 ppm-years ofbenzene
have a lifetime excess tumor probability
that appears to be less than 0.01 (13), in
contrast to the lower bound prediction
from the above model. The 95% UCL unit
risk estimates would tend to overpredict
true risks even more.
In summary, benzene risk assessment can
be improved first by using a model ofben-
zene risks that better reflects relevant ben-
zene biology. The AUC dose metric is no
longer plausible in light ofcurrent knowl-
edge of benzene biology. The second way
benzene risk assessment can be improved is
by including model uncertainty in the
uncertainty analysis. The possibility of
model error must be addressed to accurately
quantify benzene risks and uncertainties
about them.
Both of these improvements are
discussed in the following sections. The
intended result is a set of benzene risk
models that better agree with available
human data and that more accurately
predict human risks at low levels of
benzene exposure.
Methods For Improving
Benzene Risk Assessment
The following main technical ideas and
methods may be used to construct new
benzene risk models.
Causal Decomposition ofthe Cancer
Risk Process. Instead of trying to quantify
the relation between dose and response
probability directly, it is useful to decom-
pose the causal relation between exposure
history and tumor probability into biologi-
cally meaningful causal links called "micro-
relations" to quantify these links, and then
to estimate the full dose-response relation
by composing its constituent microrela-
tions. As an example, the dose-response
relation for benzene can be described as the
composition of two micorelations, one
linking administered dose to internal dose
of benzene metabolites, the other linking
internal dose to tumor probability.
Model-free Curve Fitting. Instead of
selecting the multistage model or another
specific statistical risk model as the only
model to be considered, it is potentially
more realistic to express the cumulative
tumor hazard as an unknown function of
dose. If it is sufficiently smooth, this
unknown function may be expanded as a
convergent series (i.e., expressed as a
weighted sum of orthonormal basis func-
tions), and the coefficients of the first few
terms may be estimated from data. This
provides a data-driven, model-free approxi-
mation to the true but unknown function
(14). A similar but less sophisticated
approach is to expand the unknown func-
tion around zero as a MacLaurin power
series. This has the advantage for risk
analysis purposes that the power series
model may then be interpreted as a multi-
stage model with unconstrained coeffi-
cients, i.e., coefficients not constrained to
be nonnegative. Leaving the coefficients
unconstrained may be more realistic than
constraining them to be nonnegative if the
effects ofexposure on cell proliferation and
cytotoxicity are considered.
Maximum Entropy Bayesian Monte-
Carlo Uncertainty Analysis. Instead of
the qj* methodology's asymptotic approach
to uncertainty analysis, the following
approach may be taken: a) Let the prior
probability distributions for the true but
unknown response probability in each dose
group be uniformly distributed between 0
and 1 (corresponding to a minimum of a
priori assumptions). Use Bayes' Rule to
condition this prior distribution on the
observed data, i.e., on the number of ani-
mals exposed and the number responding
in each dose group. The result is a poster-
ior distribution for the true but unknown
response probability in each dose group.
b) Sample many times from these distribu-
tions (Monte-Carlo sampling) and pass a
model-free dose-response curve through
each set of sampled tumor probability
values. In our implementation ofthis idea,
polynomial regression was used to estimate
the coefficients ofthe first few terms in the
power series expansion of the cumulative
tumor hazard function, considercd as an
unknown function of dose. The result is a
Monte-Carlo distribution of the entire
dose-response curve. If there were no
uncertainty about the true response proba-
bilities, they would uniquely determine a
single dose-response curve, namely, the
polynomial of lowest order that passes
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through them. Because the true response
probabilities are not completely deter-
mined by experimental data due to sam-
pling variability, a probability distribution
of possible dose-response curves results.
This distribution directly determines the
upper 95% limit on the low-dose slope of
the dose-response function, as well as a
wealth of other information useful for
characterizing uncertainty about the
dose-response function.
Biologicaly Based Computer Simula-
tion Models. The causal decomposition
framework suggests that the age-specific
hazard rate for cancer (AML) induction by
benzene depends on the administered dose
history through two sets ofvariables: the
internal dose of benzene metabolites (the
output ofa PBPK model) on the one hand,
and the product ofhematotoxic and geno-
toxic effects (if any) on the other. A non-
linear feedback control model is introduced
to quantify the potential effects ofbenzene
exposure on the granulocyte-macrophage
(GM) lineage, specifically among prolifer-
ating cells (e.g., CFU-GM cells) that may
be involved in acute myeloid leukemia
(AML) induction. Although this model has
not yet been validated for benzene, its pre-
dictions agree with empirical data in
important respects, providing potential
insights into why AUC dose metrics are
inappropriate and how risk may vary with
the time pattern of benzene administra-
tion. Model results suggest that no single
definition or measure of dose can ade-
quately summarize the contributions to
benzene-induced hematotoxicity and AML
risk from different detailed histories of
benzene administration. In general, the
dose-time-response relation for benzene
may be too complicated for a dose metric
to exist. Instead, dynamic simulation mod-
els must be used to calculate the effects
of different administered dose histories.
Details ofthese methods are discussed next.
Maximum-entropy Bayesian
Monte-Carlo Uncertainty
Analysis
Suppose that prior to looking at the data,
we wish to make only a "minimum-com-
mitment" assumption about the true value
of the response probability p(x) associated
with dose x. This may be done by assign-
ing to each p(x) a uniform probability
density so that, a priori, p(x) is considered
equally likely to have any of its possible
values (between 0 and 1) (15). A:lthough
stronger prior assumptions can be intro-
duced by placing a priori constraints on the
maximum-entropy joint prior density of
thep(x) values-for example, by requiring
the p(x) values to increase with x-such
constraints may express requirements that,
against a researcher's expectations, do not
hold in biological reality. In the absence of
definitive biological knowledge, it seems
safer to avoid introducing such a priori
assumptions, instead letting the shape ofthe
p(x) curve be learned directly from the data.
This may be done by conditioning the prior
probability density function on the experi-
mental data using Bayes' Rule. Suppose the
experimental data consist ofthe set
D={x, n(x), r(x) for Mvalues ofx}
(experimental data)
where M is the number of dose groups,
then the revised a posteriori probability
density forp(x) based on the observed data
point [n(x), r(x)] (and assuming the maxi-
mum-entropy, i.e., uniform, prior density
U[O, 1] with no assumed constraints inter-
relating the p(x) values for different values
ofx) is a beta distribution with parameters
n(x)r(x) + 1 and [1-r(x)]n(x) + 1. This
has the mean value
E[p(x) D]= E[p(x) n(x), r(x)]
= [r(x)n(x) + 1]/[n(x) +2]
[posterior mean ofp(x) D].
The beta posterior distribution forp(x) thus
has a mean value that is close to its observed
sample value of r(x) when n(x) is large;
moreover, the variance ofthe beta distribu-
tion is a decreasing function ofn(x) (16).
Once the posterior distribution ofeach
p(x) value has been determined, M-vectors
ofpossible response probabilities (one for
each of the Mdose groups) may be ran-
domly sampled from these distributions.
Each such M-vector determines a corre-
sponding dose-response curve, via any of
several curve-fitting techniques. For illus-
tration, we will use the relatively simplistic
techniques (14) ofpolynomial regression.
The mathematical details are as follows:
The tumor probability for an animal
exposed to dose x may be expressed with-
out loss ofgenerality as:
p(x) = l-exp[-h(x)],
where h(x) is the cumulative tumor hazard
associated with dose x. This is a mathemat-
ical identity following from the definition
of cumulative hazard. Next, the unknown
cumulative hazard function is approxi-
mated by the first few terms of a power
series expansion around zero as:
h(x)=qo+qlx+q2x2+...+qM_lxM-1
where M is the number of dose groups.
For simplicity, the following exposition
assumes that M = 4, as in Table 1. (The
formulas hold for all M. 2.) The vector of
cumulative hazards, denoted by
h=(hi,h2,h3,h4),
is determined from the values of the
response probabilities (sampled from their
appropriate P distributions) via the inverse
transformation
h1 =-ln[1-pj],
wherepi denotes the sampled value of
the tumor probability for dose group j.
This operation may be summarized by the
equation
h=-ln(1 -p),
if it is understood that the transform is
applied component-by-component to the
elements ofp, the vector ofresponse prob-
abilities, to obtain the corresponding com-
ponents of h. (This is consistent with the
notation in several popular mathematical
computing software packages, although it
does not agree with standard vector algebra
notation.) The coefficient vector
q=(qo,ql,q2,q3)
can now be solved for from h and the dif-
ferent doses used in the experiment. The
system oflinear equations
hi = qo + qlxl + q2x12 + q3X 2
2 =qo + qlx2 + q2X22 + q3X22
h= qo + q1x3 + q2X32 + q3X32
4= qo +q1x4 +q2x42 + q3X42
can be expressed compactly in vector-
matrix notation as
h= qX
whereXis the matrix with (1, xj2, X2) T
as itsjth column. (The equation h= qX
holds also for M >4 dose groups, with the
quantities h, q, and Xextended in the
obvious way.) Xis known and h can be
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estimated from the observed tumor inci-
dence rates. The corresponding value of q
is determined as follows:
q=hX-1.
The matrix inverse X-l can be found
numerically; alternatively, the special struc-
ture ofXcan be used to develop a simple,
closed-form expression for the ijth element
ofits inverse.
Repeating the sampling of response
probability M-vectors many times gives a
Monte-Carlo sampling distribution of
dose-response curves. Each sampled set of
tumor probabilities, p, undergoes the
following sequence oftransformations:
p--ln(I-p) = h- hX-1 = q-p(x)
= 1-exp[-(qo+qlx+q2x +q3x3].
Thus, each p determines a corresponding
dose-response curve expressed as a function
of x at the right end of this sequence.
Therefore, the beta distributions of the
components ofp imply a corresponding
probability distribution for dose-response
curves. This distribution ofcurves reflects
the posterior uncertainty, after conditioning
on the experimental data, about the true but
unknown p(x) values. Figure 1 shows the
data flowdiagram for the entire algorithm.
The Monte-Carlo distribution ofdose-
response curves allows a much richer char-
acterization of uncertainties than does qi*
analysis. Not only can the value ofthe low-
dose slope be determined such that 95% of
all of the sampled dose-response curves
have smaller slopes-the analog to the ql*
value in traditional analysis-but other
detailed questions about the probable shape
of the dose-response function can also be
answered. For example, the probability
distribution of the dose level at which a
given level ofrisk (such as 1 E-06) is first
exceeded can be determined from the
Monte-Carlo sample of dose-response
curves. The conditional probability distrib-
ution of the risk at one dose level given
assumptions about the risk at other dose
levels can also be determined.
Methodsfor a Biologically
Based Causal Decomposition
of Dose-Response Models
The causal relation between the admin-
istered dose history and the probability
that a tumor develops by anyspecified time
is thought to be mediated by several
biological phenomena, including benzene
Figure 1. Data flow for the uncertainty analysis. Probability distributions for the true response probability in each
dose group (denoted by Pjfor group j) are derived by conditioning maximum entropy (uniform) priors on observed
experimental data, leading to beta distributions. [The cumulative density functions (CDFs), representing these beta
distributions are shown in Figure 2.] The CDF for each response probability is transformed to a corresponding CDF
for a cumulative hazard rate via the identity hj=-ln(l-Pj). The vector of cumulative hazard rates is used to solve
forthe vector of coefficients in a polynomial regression model via the formula q=X-1h. Finally, the coefficients in
q are used to compute the risk for each of several doses, x, via the formula p(x) = 1 - expl-h(x)]=
1-expl-(qo+q1x+q2i2+...+q/e)].
metabolism and pharmacokinetics, ben-
zene-induced cytotoxicity and genotoxicity
in the bone marrow, and perhaps effects on
the immune system. These phenomena are
typically easier to observe experimentally
than tumor risk itself. To discuss how they
may be used to improve benzene risk assess-
ment, it is useful to introduce the notation
(a II b) = time historyofquantity a
determined by the time history
ofquantity b.
This notation is intended to imply that a
and b are time-varying quantities, with the
history of a up to and including any
moment tbeing completely determined by
the history of b up to the same moment.
Other constants or parameters may have to
be specified for the history {b(t), 0.<r <t}
to uniquely determine the history of{a(T),
0 < T < t} for every value of t such that
0<t. T, where 0 is the time of the
exposed animal's birth and Tis the time of
its death. Ifso, these additional quantities
may be listed after b following the "causal
conditional" sign 11 in the above notation.
For example, the dose-time-response rela-
tion between benzene exposure and AML
risk may be denoted by
(p1lx)
to indicate that the probability oftumor by
any time t is determined by the history of
benzene exposures up to time t. Another
suggested notation for a closely related
concept is
read as "the history ofxdetermines the his-
tory ofp." By contrast, {pII x} might be
read as "the history ofp that is determined
by the history of x." The curly brackets
enclose individual time-varying quantities,
or histories; thus, for example, {x} is an
abbreviation ofthe more explicit notation
{x(t), 0<t. T}.
Now, suppose that AML risk depends
on administered benzene only because of
the formation of one or more benzene
metabolites. Letting fyi denote the history
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(i.e., the time course) of the vector of
metabolites in different physiological com-
partments over time, the causal situation
may be diagrammed as
{x} -*{y}- {p}.
In other words, {x} determines {y} and {y}
determines {p}. Thus, the administered
dose-time-response relation (pII x) may be
decomposed as
({x}<-{y}) *Qy}op),
where * is the composition operator for
composing consecutive mappings. This
decomposition, based on internal dose
of metabolites, may be expressed in the
equivalent form
(p lIX) =(p Ily) *(yliX).
The component (y II x) corresponds to the
input-output relation of a physiologically
based pharmacokinetics (PBPK) model, i.e.,
it maps administered dose histories {x} into
resulting time courses {y} ofbenzene and its
metabolites in different physiological com-
partments. The microrelation (pIIy) repre-
sents an internal dose-response function.
According to recent biological theories
ofcarcinogenesis, most cancer risks can be
expressed in terms of the following
microrelations:
a PBPK model, represented by the link
a cytotoxicity and cell kinetics model,
{y}-{IN;
a genotoxicity and cytogenetics effect
model, y}-{1P};
a model ofcell initiation, {N, p} -* {II;
a hazard rate model, {I, p} -*{h};
a time-to-tumor model, {h} ->{p}.
In these links, the symbols are interpreted
for benzene-induced AML as follows: {x} =
administered dose history; {y} = metabo-
lite history, giving the time courses ofcon-
centrations of benzene and benzene
metabolites in different physiological com-
partments (e.g., blood, bone marrow, fat,
muscle, richly perfused tissue, poorly per-
fused tissue, and various organ groups);
{N} = time course of hematopoietic cell
population sizes; {p} = history ofcell transi-
tion rate parameters (including birth, death,
differentiation, and carcinogenic trans-
formation rates); {I} = time course of a
distinguished "initiated" (premalignant)
cell population for AML; {h} = cumulative
hazard function, giving the age-specific or
time-specific cumulative hazard for AML
induction; and {p} = history of tumor
probability as a function of time. Vector
quantities are indicated in boldface.
Notation of the form {a, b} -* {c} means
that the history {c} is determined by the
conjunction of histories {a} and {b}. Note
that, as it is defined here, the quantityp(t)
is greater than the probability of a
detectable neoplasm being initiated by
time t. To be detected, two further things
must occur after a malignant cell forms:
a) It must escape immune system surveil-
lance and control; and b) it must progress
to a detectable size.
ATwo-stageStochastic Model
ofCancerInduction
The complete causal model for cancer
induction in a two-stage stochastic model
of carcinogenesis is composed from the
preceding microrelations according to the
following diagram:
{x}-*{y}-{p, N}->{p2,I}-->{h}-*{p}.
Here, the initiated population, I, is inter-
preted as a stochastic process (a birth-
death process with immigration from the
"normal" stem cell compartment), and
only its probability law is determined by
the data {p,N}. The links in this causal
chain may be quantified with the help of
the following biomathematical model
equations
({h}-{p}) [1]
This link is quantified via the mathematical
identity
p(t)= 1 -exp[-h(t)].
Here, p(t) is the probability that at least
one malignant cell is initiated by time t.
Interpretively, if a randomly occurring
event (formation of a malignant cell)
occurs at a constant average rate ofa times
per year, then the probability that it has
not occurred after tyears is exp(-at). The
probability that it occurs at least once by
time tis therefore 1 -exp(-at). The above
identity generalizes this to the case oftime-
varying occurrence rates, a(t). The cumu-
lative hazard h(t) is the integrated value of
a(t) (its AUC) up through time t. Ifa is
constant, then h(t) =at.
{p2,II}- {h} [2]
This link is quantified via the formula
dh(t)/dt= a(t) = P2WIW,
where 1P2(t) is the transformation rate from
initiated to malignant cells (per initiated
cell per unit time) at time t. This formula
has the common-sense interpretation that
the expected number of malignant cells
being formed at time t, namely a(t), is the
product of the number of cells at risk of
malignant transformation, I(t), and the
rate at which transformations occur, p2(t).
{p,N}J-{p2,I} [3]
This link is quantified via a stochastic
differential equation with
dE[I(t)]/dt=
[ibt) - d(t) - P2(t) I(At) +PI(t)NI(t).
Here, b(t) and d(t) are birth and death
rates and pl(t) and1P2(t) are transformation
rates (all per cell per unit time); all four are
components of the parameter vector p(t).
Similarly, N1(t) refers to a component of
N(t) (e.g., early myeloid hematopoietic
progenitor cells).
y} {p, N} [4]
This link describes the cytotoxic, cytoge-
netic, and genotoxic effects of benzene
metabolites on different cell populations.
At present, sufficient in vivo experimental
data and biological knowledge to reliably
quantify this link are not available. Instead,
therefore, the link
{x}->{ji,N}
will be quantified using curve-fitting tech-
niques and experimental data.
{x}-> y} [5]
This link can be quantified for benzene
using any ofseveral published PBPK mod-
els ofthe dynamics ofbenzene metabolism,
distribution, and elimination (17,18).
Ifeach link can be quantified, then the
links can be composed to obtain the total
dose-time-response relation
({x} ->{pl) =({x} -. {y}) *(fyi -o{p,N})
*({p, Ie {h-})-> {p1)I
*({P2,II}- th}) *({h} {p}).
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This may be written more compactly as:
(pll1x) =(pll1h) *(hlIIP2,I)
*(p2 Illp,N)*(p,Nlly)
*(ylIx).
However, this is only one ofmany possible
decompositions. It is not the most useful
one to use with existing benzene data since
the component (p, NlIy) is highly uncer-
tain. Two alternative decompositions that
can better use available data are
(p11 x) =(plly)*(yl x)
=(pllh)*(hllP2,I)*(p2,IiIp,N)
*(p, NlIx).
Different decompositions ofthe dose-time-
response relation suggest different statistical
strategies for quantifying it. For example,
(pllx), the undecomposed relation,
may be estimated by fitting curves or
models to experimental data on admin-
istered doses and resulting tumors. This
is the traditional approach illustrated
already for the data in Table 1 using
the U.S. EPA data (5) risk assessment
as an example.
(plly) *(yII x) involves quantifying both
the PBPK component, (yII x), based on
experimental data on administered doses
and resulting metabolite levels and also
the internal dose-time-response rela-
tion, (plly), based on experimental data
on metabolite levels and tumor rates.
(p h) * (hII p2, I) * (p2,III p, N)
*(p, NIl x) involves quantifying the
relation (pi, NII x) based on experimen-
tal data on administered doses and cell
level responses (cell proliferation rates,
population sizes, cytotoxic impacts, and
cytogenetic and genotoxic transforma-
tion rates). For the remaining compo-
nents, both (pl h) and (hIl P2,I) are
obtained from the previously described
mathematical equations. (p2, Ip,N)
involves identifying the cell population
corresponding to Iand the transforma-
tion corresponding to P2-
Each of these strategies for decomposing
and quantifying risk makes use ofdifferent
data and has its own advantages. Each will
be used subsequently in developing results
on benzene risks.
Quantifying Microrelations
by Simulating Biological
Processes: PBPK and Cyto-
toxicity Modelsfor Benzene
To quantify a relation such as (yII x), it
is usually necessary to build a dynamic
simulation model that can accept time
series histories {x} as inputs and calculate
resulting output histories such as {y}. Such
models typically take the form of systems
ofnonlinear ordinary or partial differential
equations. In the simplest cases, the output
history can be calculated from the input
history by iterating the following discrete-
time approximation for small values ofthe
time step, s:
y(t+s)=y(t)+g[x(t),y(t)]s
(Euler's method ofnumerical integration)
where the instantaneous rate ofchange ofy
at time tis given by the formula
dy/dt =g[x(t),y(t)].
The transition rate function g, indicated in
bold because it is a vector function, deter-
mines the time evolution ofyfrom its own
current value and the concurrent value of
the input, x. In practice, g is obtained by
biomathematical modeling of the specific
biological system involved.
Two examples oflinks for which dyna-
mic models have been developed for benzene
are PBPK models and cytotoxicity models.
PBPKModelsforBenzene
The microrelation (yII x) is quantified by
PBPK models ofbenzene metabolism and
distribution. Several such models have
been published and are available for use
(1,17,18). For risk assessment purposes, we
prefer the human and animal PBPK models
ofTravis et al. (17). These models quantify
total benzene metabolites and do not track
circulating metabolites. On the positive
side, they have been extensively compared
to and validated with human and animal
experimental data. The details ofthe PBPK
models are discussed byTravis et al. (17).
Henderson et al. (19) present the fol-
lowing three empirical y(x) data points for
mice exposed to benzene via oral gavage, as
in Table 1: y(12) = 10; y(40) = 25; and
y(150) = 50. In each of these y(x) data
points, the xvalue is the administered dose
measured in mg ofbenzene per kg ofani-
mal body weight and the y value is the
resulting internal dose, defined as the total
amount of metabolites formed in mg
divided by the mouse body weight in kg.
The internal doses y(x) corresponding to
the administered dose levels of x = 0, 25,
50, and 100 mg/kg/day used in the NTP
mouse bioassay experiment in Table 1 have
not been directly measured. However,
linear interpolation among these three
published data points gives interpolated
values of/y*(25) = 18.25; y/(50) = 30; and
y*(100) = 46. Alternatively, we can follow
Bailer and Hoel (6) in assuming that the
[x, y(x)] points fall approximately on a
nonlinear regression curve having the
Michaelis-Menten form y(x) = Vxl(K+ x)
where m = (V, K) is a parameter vector to
be estimated from data. Least-squares esti-
mation using the preceding three data
points gives K* = 80.75, V* = 76.4, corre-
sponding to y*(25) = 18.1, y*(50) = 29.2,
andy*(100) = 42. These values are slightly
less than the linearly interpolated values of
y*(25) = 18.25;y*(50) = 30; andy*(100) =
46. The least-squares regression procedure
smoothes out sampling variability and mea-
surement error to the extent that the under-
lying Michaelis-Menten model is correct.
Given that the regression and interpolation
values are close and that the former are
more conservative, the Michaelis-Menten
regression estimates could be used in the
rest ofthe analysis.
An alternative, more biologically based
modeling approach is to use a benzene
PBPK model to simulate the pharmacoki-
netic and metabolic processes that convert
administered doses to internal doses. Cur-
rent PBPK models accomplish this simula-
tion by representing the flow of benzene
from compartment j to compartment i at
time t(for nonmetabolizing compartments)
by the equation
fi(t) =kij[Cj(t -QWI()PJ .
The rate ofchange in the concentration of
benzene in compartment iat time tis thus
dCi(t)/dt=Xj[fij(t)-fji(t)],
the flow into ifromjminus the flow out of
i intoj. (Ifj is not adjacent to i, the flow
between them is zero.) Ifbenzene is metab-
olized in compartment i, such as liver or
bone marrow, then dCi(t)ldtalso includes
a term [-VmaxCi(t)/Pi]/[Km + Ci(t)/PJ],
where Vmax and Km are the Michaelis-
Menten parameters for the aqueous com-
ponent of the compartment. Given the
values ofthe pharmacokinetic parameters
kij and Pi and the metabolic parameters
Vmaxand Km, this system of differential
equations can easily be integrated numeri-
cally to solve for the time series {C1(t)}. In
current PBPK models for benzene, the
metabolic parameters Vmax and km are
highly uncertain: they have been estimated
by Medinsky et al. (18) and Travis et al.
(17) by seeking values that would make
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model outputs match available data as well
as possible.
The blood:tissue and blood:air parti-
tion coefficients Pi for benzene are avail-
able in the literature. Medinsky et al. (18)
provide values ofblood:tissue and blood:air
partition coefficients Pi for i = liver, fat,
poorly perfused tissues, richly perfused tis-
sues, and air. Travis et al. (17) identified
ranges of Pi values from the literature for
i = fat, liver, muscle, organs (corresponding
to richly perfused tissues) and air and then
chose values within these ranges that
caused the PBPK model predictions to best
fit available data. The flow rate parame-
ters kij are determined by PBPK theory
as follows:
* If the flow is from j = arterial blood
to i= a tissue compartment, then
kij = Q/Vi, the blood flow rate (in liters
per minute) through compartment i
divided by the volume (in liters) of
compartment i. Values of the physio-
logical constants Q and Vi have been
estimated for rats, mice, humans, and
other species (20).
* If the flow is from j = alveolar air to
i= arterial blood (or vice versa), then
the value ofk is assumed to be so large
that theflowf,1ij(t) = ki,[Cj(t)-Ci(t)/N
can be modeled as adjusting to equilib-
rium instantaneously. (N denotes the
blood:air partition coefficient.) Instead
of having to estimate ki1, therefore,
the equilibrium condition Caiv(t) =
Ca,(t)INis assumed.
* The total flow of benzene into mixed
venous blood from tissues per unit time
is the sum over all tissue groups, i, of
QC,(t)/Pi, while the total flow ofblood
into the venous side of the circulation
per unit time is just Q, the circulation
flux (1/min), which is equal to the total
cardiac output rate. Ifit is assumed that
the volume ofthe venous system is neg-
ligible, then the concentration ofben-
zene in the venous blood will be the
sum over i of (Q./Q)Ci(t)lPi, i.e., it
will be the average concentration of
benzene in blood entering the mixed
venous blood. This determines the
(approximate) value ofCve,(t), the con-
centration ofbenzene in mixed venous
blood at time t.
In addition to these flow rate and equi-
libration assumptions, the following flow
balance constraint is also assumed:
Cart(t)(Qalv +N+ Q) = IQalvCinh(t)
+y-iQClXt)/Pil
implying that
Cart(t) =[QlvCinh(t) + iEQC(t)/Pi /
(Qlv/N+Q).
This equates the total inflow of benzene
per unit time into the alveolar-air-and-
arterial-blood compartment to the total
outflow ofbenzene per unit time from that
compartment.
These assumptions and parameter
estimates allow the time series ofbenzene
concentrations in each compartment to be
determined from the inhalation exposure
time series {Cinh(t)}. If the dose adminis-
tration route is oral gavage or injection (sc
or ip), the PBPK model must be extended
to allow for transfer of the administered
bolus dose into the rest ofthe system. For
oral gavage, the simplest expedient is to
assume a first-order gastric absorption con-
stant (transfer rate) from the GI tract to
the liver. Both Medinsky et al. (18) and
Travis et al. (17) make this assumption
and both estimate similar rate constants in
mice-0.032/min according to Travis
et al. and 0.05/min according to Medinsky
et al. [However, the gastrointestinal trans-
fer rate constant estimated for rats is 0.0042
according to Medinsky et al. (18) and 0.01
according to Travis et al. (17).]
We have reimplemented the Travis et
al. PBPK model for benzene (17), incorpo-
rating the preceding modeling assumptions
and parameter values. This model has been
extensively compared against both human
and animal data on time courses of ben-
zene concentrations in expired air, blood,
and bone marrow during and following
exposures to benzene via inhalation, oral
gavage, and injection. It provides a useful
fit to nearly all the available data sets, as
discussed in detail byTravis et al. (17). The
resulting simulation model for metabolism
oforal gavage doses in mice predicts values
for internal doses slightly greater than the
ones from the Michaelis-Menten regression
model. Table 2 compares the predictions
from the PBPK and Michaelis-Menten
internal dose models.
The Michaelis-Menten model in Table 2
was fit to the three empirical data points
from which the parameter values K* =
80.75 and V* =76.4 were estimated. A bet-
ter fit to the PBPK model output is given by
the revised Michaelis-Menten model
y*(x) =77.5x/(74.33 +x). This curve pro-
vides a compact approximation ofthe PBPK
results. At the National Toxicology Program
(NTP) dose levels of x=25, 50, and
75 mg/kg, it predicts internal doses of
y*(25) = 19.5, y*(50) =31.2, andy*(100) =
45.5, compared to the PBPK model predic-
tions ofy*(25) = 19.0, y*(50) = 30.1, and
y*(100) = 44.6. Agreement at other points is
even closer. Thus, y*(x) = 77.5x/(74.33 +x)
provides a useful analytic approximation
to the PBPK model for predicting total
metabolites formed from oral gavage doses.
CytotoxicityandCellKinetics
ModelsforBenzene
The link (Nil x) may be quantified by
biomathematical simulation models of
granulopoiesis and hematotoxicity. Such
models have been previously developed
and tested against experimental data in
mice for benzene (21) and in dogs for the
immunosuppressive and myelotoxic agent
cyclophosphamide (CP) (22). Although
such models are relatively immature and
exploratory compared to PBPK models,
they do synthesize large amounts of rele-
vant biological experimental data and may
prove useful in future efforts to improve
benzene dose-time-response modeling.
A computer simulation model of
benzene-induced hematotoxicity is cur-
rently being developed. While it would be
premature to rely on it as a basis for ben-
zene risk assessment, it offers potential
insights that may be useful enough to jus-
tify a briefoutline ofthe model's main fea-
tures. It is based primarily on the model of
Steinbach et al. (22) updated with benzene
cytotoxicity parameters from Scheding et
al. (21). We have validated the model with
published human clinical data for CP
(23). The main model consists of a set of
compartments representing cell popula-
tions, linked by flow equations with flow
rate parameters that change over time in
response to changes in the sizes of the cell
populations. Several nonlinear feedback
control laws operate to restore the cell
population sizes to their stable equilibrium
Table 2. Mouse internal doses of benzene metabolites
(mg/kg) produced from different oral gavage doses, as
predicted byvarious models.
Dose
level x
5
10
12
25
40
50
100
150
Observed
values
10
25
50
Predicted y(x)values
Michaelis-Menten PBPK
0.93 1
4.5 4.9
8.4 9.2
9.9 10.7
18.1 19.0
25.3 26.2
29.2 30.1
42.3 44.6
49.7 54.5
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values following any small perturbation,
e.g., due to inhalation of benzene. These
feedback control laws are not powerful
enough to maintain or restore equilibrium
cell population levels ifsufficiently intense
exposure continues, however. Even after
cessation of dosing, the system may not
return to equilibrium for manyweeks.
The compartments of the cell kinetics
and hematotoxicity model are defined and
abbreviated as follows:
* S = early myeloid stem cells and
hematopoietic progenitor cells (HPCs).
These cells are further subdivided into
two subpopulations:
cycling_HPCs = actively cycling
HPCs (i.e., those participating in the
mitotic cycle);
resting_HPCs = resting or dormant
HPCs (not actively cycling).
* CFU = granulopoietic committed stem
cells. Biologically, these correspond
roughly to CFU-GM cells, i.e., to early
myeloid cells that can form GM
colonies. To model accurately both the
mean and the variance of transit times
through this compartment, it is neces-
sary to account for the age structure of
the CFU-GM population. The partial
differential equation (PDE) describing
the time evolution ofthe age-structured
population is approximated by dividing
the compartment into 10 fictitious sub-
compartments representing cells ofdif-
ferent ages. The age/maturity structure
ofthis population also matters in deter-
mining the dynamic response of the
hematopoietic system to CP-induced
stresses. Subdividing it into 10 subcom-
partments allows shifts in its age com-
position to be approximated.
* P = proliferative pool, consisting
roughly of myeloblasts, promyelocytes,
and myelocytes. This aggregate com-
partment is also subdivided into 10
subcompartments to simulate the
changing age structure ofthe prolifera-
tive subpopulation over time.
* M = maturation pool, in which cells
finish maturing and lose their remaining
proliferation and differentiation capaci-
ties, thus becoming no longer suscepti-
ble to carcinogenic transformations.
* R = bone marrow reserve of mature
granulocytes. Granulocytes are released
from this compartment to peripheral
blood as needed to replace losses due to
normal cell senescence and death or to
emergencies such as bleeding.
* B = mature granulocytes in circulating
blood. In comparing model predictions
to experimental data, this compartment
represents an approximation to white
blood cells (WBCs) (although lym-
phoid cells are not modeled).
These cell populations are the compo-
nents ofthe vector Nin the microrelation
(NI x). Other aspects of granulopoiesis,
such as the shift ofsome hematopoiesis to
the spleen under stress, deterioration ofthe
stromal microenvironment of the bone
marrow over time, or migration of stem
cells from the marrow into the peripheral
blood and back are ignored in this model
since their significance for the dosing
scenarios considered is expected to be small.
The flow equations linking the com-
partments ofthe model (22) express three
key ideas: a) the flux ofliving cells out of
each compartment enters its downstream
neighbor; b) the flux of dead cells from
each proliferative compartment is propor-
tional to the number of cells currently in
the compartment and to the concentration
of administered benzene weighted by a
compartment-specific cytotoxicity parame-
ter; and c) the magnitude ofthe flux out of
a compartment is directly proportional to
the compartment's current size (i.e., to the
number ofcells in it) and inversely propor-
tional to the transit time of cells through
the compartment.
The number ofcells in any ofthe com-
partments at any time is found from the
flow equations by incrementing the imme-
diately previous number to reflect inflows
from the upstream compartment and
amplifications due to cell divisions (for the
early, proliferative compartments); and by
decrementing the result to reflect outflows
to downstream compartments and losses
due to cell death. Cell death rates due to
benzene metabolites (per susceptible cell
per unit time) are assumed to depend on
administered concentration ofbenzene, as
discussed by Scheding et al. (21).
The values ofkey flow rate parameters
are determined via nonlinear feedback con-
trol equations from the sizes ofvarious cell
populations. The hematopoietic system
exerts several forms of feedback control to
regulate its own behavior and compensate
for cytotoxic and other stresses (21). Based
on several decades ofexperimental data in
animal models, the following five specific
quantities are controlled by feedback
control loops in the model.
HPC_recruitment_rate = fractional
recruitment rate of resting HPCs, defined
as the fraction of resting HPCs recruited
into active cycling per unit time. This rate
is controlled not only by the concurrent
numbers of resting and cycling stem cells,
but also by the sizes ofthe downstream cell
populations in the CFU-GM and subse-
quent compartments up through and
including the bone marrow reserve. If the
more mature cell populations depart from
their steady-state levels in response to
hematopoietic stresses due to dosing, the
recruitment and production of stem cells
counter-adjusts to help move the system
back toward its equilibrium levels of
these populations.
HPC_differentiation-fraction = The
fraction of HPCs that differentiate (rather
than self-renewing). A simplified model of
the cell cycle is used for stem cells, indicat-
ing the fraction (A/S) that are actively
dividing at each moment. As each cell
completes the mitotic cycle, it either differ-
entiates, making a transition into the first
CFU-GM proliferative compartment, or it
passes immediately into G1, starting the
next round ofcell division, or it lapses into
GO, the resting state. The fraction that dif-
ferentiates is determined by the current
numbers ofresting and cycling stem cells.
CFU birth_rate= fractional birth rate of
CFU-GM cells (average birth rate per CFU-
GM cell per unit time). Ifthe more mature
GM lineage downstream from these GM-
committed stem cells becomes depleted, the
division (i.e., birth) rate of the CFU-GM
cells increases to compensate. Conversely, if
the downstream cell populations are well
stocked, then the birth rate among CFU-
GM cells slows. The CFU-GM birth rate
is also affected by feed-forward from the
earlier stem cell compartment.
P_birth_rate = fractional birth rate of
proliferative cells. These cells are assumed
to respond only to signals from CFU-GM
and later cells, up through and including
the bone marrow reserve, but not to signals
from the earlier (pre-CFU-GM) stem cells.
Release_rate to_blood= fractional release
rate ofmature granulocytes from bone mar-
row reserve to peripheral blood (per reserve
cell per unit time). This rate is controlled by
a direct feedback loop from the peripheral
blood compartment; there is no longer range
control from upstream cell populations.
The nonlinear feedback control equa-
tions determining these quantities are sum-
marized in the appendix. The specific
functional forms used are empirical approx-
imations obtained by fitting smooth curves
to experimental data and to extreme or
limiting conditions (e.g., maximal birth
rates obtained under experimental condi-
tions ofmaximum stimulation). Sensitivity
analysis reveals that the exact forms ofthe
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equations are less important than their
overall shapes. Steinbach et al. (22) discuss
in greater detail the experimental basis
and the assumptions used to derive the
feedback control equations.
Using the Decomposition
Framework for RiskExtrapolation
A principle advantage ofthe causal decom-
position approach to dose-response model-
ing is that it provides an alternative to dose
metrics as a basis for risk modeling. Thus,
even though a predictively useful dose met-
ric may not exist for benzene, risks can still
be quantified and extrapolated. The princi-
ple of extrapolation is illustrated by the
following formula:
(p11X)human, inhalation =(p "Y)mouse, gavage
(y II X)human, inhalation
This formula shows that the relation
(p lly) estimated from experimental data
involving mice exposed via oral gavage can
be composed with the relation (yII x) esti-
mated from data (or from a PBPK model)
for humans exposed via inhalation. The
result is an extrapolated (across species and
route) estimate of the dose-time-response
relation (pII x). Each term in the decompo-
sition is subscripted to indicate the type of
data from which it has been estimated.
Ideally, all terms would be estimated from
the same type of data (e.g., sex, age, spe-
cies, strain, route of administration, etc.),
namely, the data type to which the risk
model as a whole is to be applied. In prac-
tice, however, ifdata for humans exposed
via inhalation (for example) are not avail-
able to quantify some of the components,
then animal data may be substituted. This
provides a method ofincorporating human
data where it is available and using only ani-
mal datawhere necessary. Models quantified
in thiswaycan subsequendy be refined when
more relevant data become available.
Results
Results ofMonte-Carlo
UncertaintyAnalysis: The Slope
ofthe Dose-Response Curve Is
Unlikelyto BePositive atthe Origin
Figures 2 to 6 show the results ofapplying
the maximum-entropy Bayesian Monte-
Carlo uncertainty analysis technique to the
data in Table 1. The posterior cumulative
distribution functions (CDFs) for the tumor
response probabilities after conditioning on
the sample sizes and observed tumor inci-
dence rates are shown in Figure 2. These
provide the input to the rest ofthe compu-
tations summarized in Figure 1. Figure 3
shows the CDF for ql. Notice that there is a
high probability (about 90%) that q, is neg-
ative, suggesting that there is no excess risk
at low doses. Figure 4 shows this explicitly:
as administered dose increases from 1
mg/kg/day to 5 mg/kg/day, the PDF for
risk shifts left. However, at 25 mg/kg/day,
the lowest dose group for which data are
available in Table 1, the risk is significantly
increased compared to the zero-dose risk.
The interpretation ofnegative risk values at
lower doses is discussed below. Figure 5
shows the expected value of the dose-
response function (the solid curve in the
middle) with 75 and 95% probability bands
around it. These bands are to be interpreted
in terms ofthe Monte-Carlo-derived poster-
ior PDF or CDF for the response probabil-
ity at each dose level rather than in terms of
classical hypothesis testing. Thus, they
replace the 75 and 95% upper and lower
confidence limits that would be derived
from the asymptotic X2 distribution using a
traditional qj* approach. Figure 6 shows
analogous results for excess risk, defined as
total risk minus background (zero-dose)
risk. The 95% upper probability band for
excess risk has a positive slope of0.004 and
is linear at low doses. This is about halfthe
value of qi* derived using the traditional
(GLOBAL'82) approach.
All these results are based on simple
polynomial regression as a curve-fitting tech-
nique, as described in the methods section.
More sophisticated nonparametric smooth-
ing (e.g., splines) could be used instead.
Results ofTraditionalMul
Model UsingPBPKIntenY
Doses:The Dose-Response Curve
Has ZeroSlope attheOrign
The strategy of decomposing the benzene
dose-response relation as
(pIIx)=(pIIy)*(yllx)
has been implemented for the data in
Table 1 (25). The internal dose microrela-
tion (y II x) for mice was quantified in
three steps: a) The PBPK model ofTravis
et al. (17) was used to calculate the steady-
state amounts oftotal benzene metabolites
produced per day from different amounts
of benzene administered per day. b) A
nonlinear (Michaelis-Menten) regression
model was used to quantify the relation
between x, the administered daily dose of
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Figure 2. Beta posterior distributions for the true
response probability in each dose group.
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Figure 3. Cumulative probability density function (CDF)
forq1. The CDF is obtained via Monte-Carlo simulation,
by propagating numbers sampled from the beta distrib-
utions on the left of Figure 1 through the rest of the
diagram. The CDF for each derived quantity in Figure 1
is obtained via an algebraic combination of the (sam-
pled) values ofthe quantities pointing into it.
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Figure 4. Sensitivity analysis of the probability density
function of risk to different administered concentrations.
At doses x=0.2 and x=1 mg/kg/day, the probability
mass is concentrated near zero (and is less than 0.1).
For x=5 mg/kg/day, the probability mass is shifted
left: the probability of a positive tumor response is less
than at lower doses. At x=25 mg/kg/day, however, it is
very likely thatthe risk is positive.
benzene, and y, the total amount of ben-
zene metabolites formed per day. c) The
fractions of total benzene metabolites
formed along different specific metabolic
paths (e.g., leading to hydroquinone conju-
gates, muconic acid, etc.) were quantified
based on empirical data.
The mouse PBPK model relation
between administered dose and internal dose
(defined as total benzene metabolites formed
per day mg/kg/day in mice exposed via oral
gavage to xmg/kg/day ofbenzene) was well
approximated by the following nonlinear
(Michaelis-Menten) regression model:
(Y X)mouse, gavage =76.4x/(80.75 +x)
(xin mg/kg/day via gavage)
The corresponding relation for humans
exposed to benzene inhalation derived
from a benzene PBPK model for humans
(17) was
(Yl X)human, inhalation =9.525x/(132.2+x)
(xin ppm via inhalation).
Other choices of route and dose regimen
lead to similar formulas. Each such formula
gives a useful numerical approximation of
the results of the full dynamic PBPK
model for a specific choice ofthe exposure
summary variable, x, the metabolism vari-
able, y, and for a range of administered
dose scenarios.
Next, the microrelation (pIly) was
quantified using a traditional multistage
dose-response model, taking both total
benzene metabolites and the amounts of
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Figure 5. Probability bands for the dose-response
relation. For doses below about 10 mg/kg/day, it is
unlikely that there is a positive excess tumor risk due
to benzene exposure.
metabolites formed along specific meta-
bolic pathways (corresponding to specific
components ofy) as the dose variable, and
using the tumor data in Table 1 for
response data. The internal dose versus
observed response data points for total
benzene metabolites are shown in Table 3.
The projected internal dose levels (the
y* values) in Table 3 are estimated from
the corresponding administered dose levels
(x = 0, 25, 50, and 75 mg/kg/day) using
the Michaelis-Menten statistical interpola-
tion model y*(x) = 76.4x/(80.75 +x). The
traditional multistage methodology (imple-
mented in GLOBAL '82) applied to the
internal dose estimates in Table 3 produced
the following results:
The MLE cancer probability from y
mg/kg/day of benzene metabolites (for
male B6C3F1 mice) is
(plly)= 1 -exp(-0.000019y3)
(MLE internal dose-response
model for mice).
The estimated 95% UCL for the low-dose
slope, calculatedvia the ql* methodology, is:
ql*=0.00554.
(estimated 95% UCL).
Table 3. Estimated internal dose-response functions
for mice.
Administered dose x: 0 25 50 75
mg/kg/day
Estimated dose, 0 18 29 42
y* (mg/kg/day)
% of animals with 0 8 40 74
squamous cell carcinomas
(50 animals/dose group)
---------- 0.05
- -0.25
0.5
__0.75
be 0..9X <
0.1
0 5 10 15 20 25
Dose
Figure 6. Probability bands for excess risk. The
expected excess risk (solid line) is negative at doses
below 15 mg/kg/day. However, there is a 5% (but not
a 25%) chance that it is positive even at very low
doses, as predicted by the qj* methodology.
For humans, the dose-response function is
estimated as follows:
(pll X)human, inhalation =(pl Y)human, inhalation
*(Y
IIX)human, inhalation
= (P Y)human, inhalation
*9.525x/(132.2+x).
In the absence ofspecific data from which
to estimate (pIIY)human, inhalation' the inter-
nal dose-response function estimated for
mice (the most sensitive known species,
sex, and strain) was used instead:
estimated (p I X)human, inhalation
(PIIY)mouse, gavage*9.525x/(132.2+x)
=1 -exp{-0.000019[9.525x/(132.2+X)]31
(estimated human dose-response function).
Note that the MLE model for
(PIIY)mouse, gavage has a slope of zero as y
approaches zero (and hence as xapproaches
zero). The estimated total dose-response
relation (p II X)human, inhalation is nonlinear
with a slope ofzero at x = 0. A maximum
entropy Bayesian Monte-Carlo uncertainty
analysis of the mouse internal dose-
response function (p"Y)mouse, gavage con-
firmed that there is no increase in expected
risk at doses below about 14 mg/kg/day.
Applications ofthe HumanRisk
Model to DifferentDosingScenarios
Tables 4 and 5 show the results ofapplying
the foregoing risk model to two human
exposure scenarios of practical interest: a
dailydosing scenario (Table 4) and a contin-
uous exposure scenario (Table 5). In Table
5, the risk to humans from routine expo-
sure is shown as a function ofan unknown
constant, k. This is defined as the ratio of
the steady-state, biologically effective dose
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Table 4. Estimated human dose-response model for8 hr/day lifetime inhalation exposures to benzene.
Concentration, ppm
1 5 10 25 50 100 200
Average daily internal 0.067 0.32 0.63 1.5 2.6 4.2 6.0
dose (mg/kg/day)
from PBPK model
Lifetime excess cancer 6 x 10-9 6 x10- 5x 104 6x 10-5 3 x 104 0.0014 0.004
risk, based on mouse
dose-response function
Table 5. Individual excess cancer risks from lifetime inhalation exposure to 1 ppm of benzene, for different values
of k(= mouse:human internal dose ratio).
Value of k
Dose measure Risk model 0.01 0.1 1
Administered dose 1.45 x 10-3 x+ 1.31 x 104X2 0.0016 0.0016 0.0016
Total metabolites 1.86x10-5y3 1.1 E-13 1.1 E-10 1.1 E-7
Total HQC dose 1.51 x 10-3 y3 0.8 E-13 0.8 E-10 0.8 E-7
Total MAdose 1.51 xlO-2y3 8.1 E-13 8.1 E-10 8.1 E-7
Total metabolites, two-stage lMS 6.21 x 10-4 y2 2.0 E-9 2.0 E-7 2.0 E-5
Abbreviations: HQC, hydroquinone conjugates; MA, muconic acid; LMS, linearized multistage risk model.
Table 6. Maximum likelihood linearized multistage risk models fit to male mouse squamous cell cancer incidence
data fordifferent surrogate internal dose measures and tumor end points.
y= Dose surrogate Maximum likelihood LMS risk model Description
End point-all squamous cell carcinomas
Administered dose 1.45 x 10-3 x+ 1.31 x 104 x2 Linear-quadratic
Total metabolites 1.86 x 10-5 y3 Cubic
Total HQC dose 1.51 x 10-3 y3 Cubic
Total MA dose 1.51 x10-2 y3 Cubic
AUC HQC dose 4.14 y2 + 2.44 y3 Quadratic-cubic
AUC MA dose 0.448 y2 + 0.004 y3 Quadratic-cubic
End point-squamous cell carcinomas
ofZymbal and preputial glandsa
Zymbal gland SCC 6.13 x 106 y3 Cubic
Total metabolites
Preputial gland SCC, total metabolites 1.51 x 104y2 + 8.89 x 104 y3 Quadratic-cubic
Abbreviations: LMS, linear multistage risk models; SCC, squamous cell carcinoma. "Specific tumortype end points
should only be analyzed bytime-to-tumor models thatadjust forcompeting risks due to other tumors. These quantal
models are for purposes of illustration only. From Coxand Ricci (20).
of the carcinogenic metabolite in humans
to its value in mice, assuming iow, constant
administered concentrations of benzene.
Table 6 shows that the main finding of a
zero slope for the internal dose-response
function at the origin (i.e., low-dose non-
linearity) holds for many choices of inter-
nal doses and end point. Details of the
computations summarized in Table 6, are
presented by Cox and Ricci (20).
Results ofComputerSimulation
Modeling: the Hematotoxicity
Dose-Time-Response Relation Has a
NegativeSlope atLowConcentrations
Ideally, the results of risk calculations
based on the decomposition
(pllx) =(pIly) *(yIl x)
would be cross-checked and improved using
the results ofalternative decompositions
such as
(pllx)=(pllN,p) *(N,1ll x).
Although some data are available toquantify
the cytotoxic effects on Nand the cytotoxic
and genotoxic effects on p of inhalation
exposure to benzene (7), a detailed calcula-
tion ofbenzene dose-response relations by
this decomposition analogous to the one
based on PBPK modeling ofinternal doses,
has not been done. Nonetheless, it is now
possible to provide a key component of
such a model by using a simulation model
of benzene-induced hematotoxicity.
Figures 7 to 9 show results from the bio-
logically based computer simulation model
A
5.00e+07 -
2.50e+07-
... ...... .... .........
/- - --- --.------- ----
0.00 240.00 480.00 720.00 980.00
Hours
B
0.00 240.00 480.00 720.00 980.00
Hours
--------- l0 ppm benzene
- -- 25 ppm benzene
50 ppm benzene
100 ppm benzene
- - - 200 ppm benzene
Figure 7. Computer simulations of early and late
CFU-GM responses to different benzene concentra-
tions. Curves show the simulated time courses of
CFU-GM cells-(A) earliest CFU-GM 1; (B) most
mature CFU-GM 10-in response to constant expo-
sures to (approximately) 10, 25, 50, 100, and 200 ppm
of benzene, respectively.
5.95e+08 -
2.98e+08 -
0.00 240.00 480.00 720.00 980.00
Hours
----- 24 hr between repeated doses
- --72hr between repeated doses
144 hr between repeated doses
Figure 8. Different amounts of spacing between
repeated 8-hr inhalation doses of benzene cause very
different hematopoietic responses for the same admin-
istered dose (AUC) per unit time. Curves correspond to
24, 72, and 144 hrbetween repeated doses.
used to quantify the relation (NIl x). There
are two major conclusions from this
model. a) The function N(x) = (NI x),
expressing the steady-state size of early
myeloid proliferative cell population (e.g.,
HPCs or CFU-GM) as a function of the
administered benzene concentration
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Figure 9. Steady-state relations between benzene exposure and hematopoietic cell population sizes predicted by
a dynamic simulation model. Benzene dose axis may need to be rescaled for humans.
assuming a constant exposure scenario, is a
nonmonotonic function of benzene con-
centration (Figure 9). At sufficiently low
concentrations, benzene exposure is pre-
dicted to increase cell population sizes (for
early HPCs and immature CFU-GM cells,
but not for very mature CFU-GM cells).
In Figures 7 to 9, CFU-GM1 is the earli-
est of the 10 age-structured subcompart-
ments ofthe CFU-GM population, while
CFU-GM10 is the last of these subcom-
partments. Figure 9 plots the steady-state
levels in Figure 7 against administered con-
centration. It shows that the relation
between ppm of benzene and predicted
steady-state values ofN(where Nis one of
the early CFU-GM or HPC populations)
is positive at sufficiently low concentrations
but negative at higher concentrations. If it
is conjectured that AML risk is increased
only by exposure scenarios that signifi-
cantly depress CFU-GM and/or HPC
populations (e.g., because recruitment into
active cycling or clonal expansion of pre-
leukemic stem cells becomes more likely),
then the predicted shape of the (Nll x)
relation would be consistent with the
hypothesis that benzene at sufficiently low
concentrations does not increase (and
might even decrease) AML risk. b) The
same AUC ofadministered dose may have
profoundly different effects on hematotoxi-
city depending on how it is administered
over time. For the same AUC per unit time
ofadministered benzene, higher concentra-
tions may lead to disproportionately large
hematotoxic effects (Figure 8). The
nominal administered concentration in
Figure 8 is 100 ppm. Different concentra-
tions with the same time pattern ofadmin-
istration produce similar results for a broad
range ofadministered concentrations. Since
the benzene hematotoxic potency factors in
the model were originally developed for
mice rather than for humans, however,
human data are needed to calibrate the
model more exactly for benzene.
Although the simulation model pro-
duces a wealth ofother results, it should be
developed and validated further before
being used for risk assessment. Nonethe-
less, the model-based conclusions appear to
be consistent with the results arrived at by
other methods.
Discussion
Bayesian Monte-Carlo Uncertainty
AnalysisResults
The 95% upper probability bands on low-
dose slopes for excess risk derived by
Bayesian Monte-Carlo uncertainty analysis
(Figure 6) are ofthe same order of magni-
tude as the qi * values derived by traditional
methods. However, the Monte-Carlo
uncertainty analysis in Figures 3 to 6 also
reveals a great deal of additional informa-
tion that many decision makers-includ-
ing all who follow the expected utility
paradigm of rational decision making
(23)-would consider relevant. Perhaps
most striking is the fact that the expected
value of the excess risk is negative for
administered doses smaller than about
15 mg/kg/day (Figure 6). Taken at face
value, this finding suggests that the health
protection benefits from reducing doses
below this level are very uncertain, and may
not be significantly different from zero.
Notice that while the total risk of tumor
defined as aprobability orhazard rate, must
be nonnegative, the risk due to a specific
cause such as benzene can perfectly well be
negative. For example, risk might be
reduced ifbenzene exposures in the 1 to 15
mg/g/day range were to suppress the
expression ofcarcinogenic damage (e.g., by
killing or preventing the division ofaffected
cells) or were to reduce the sizes ofthe pop-
ulations at risk of carcinogenic damage.
Since benzene was once used as a human
chemotherapeutic agent, such effects on cell
kinetics would not be completely unex-
pected. Without speculating about such
mechanisms, the interpretation ofthe nega-
tive risk values in Figures 4 through 6 is
that the expected lifetime tumor probability
at low doses is less than the expected life-
time tumorprobability at zero dose.
Traditional RiskModel
Basedon Internal Doses
The benzene risk model based on PBPK
modeling and use ofinternal doses, namely,
(p II X)human, inhalation
= 1 -exp{-0.000019[9.525x/(132.2 +x)]3},
differs significantly at low dose from the
traditional (administered dose) benzene
risk model discussed in the introduction.
For example, at x= 12 mg/kg/day, mice
form approximately y= 76.4 * 12/(80.75 +
12)= 10 mg/kg/day of total benzene
metabolites, giving a projected lifetime
cancer risk ofP*(10) = 0.019 based on the
internal dose model. By contrast, the
administered dose risk model p*(x) =
1 -exp[-(0.00145x+ 0.00013x2) gives a
predicted lifetime cancer risk level of
p*(12) = 0.035 based on the administered
dose model. Thus, fitting the dose-response
function to internal doses instead ofadmin-
istered doses changes the maximum likeli-
hood linearized multistage model from
linear-quadratic to cubic, reducing estimated
riskbyabout a factor of2 at an administered
dose level of x = 12 mg/kg/day. [This oral
gavage dose level corresponds roughly to a
6-hr inhalation dose ofabout 10 ppm based
on total metabolites formed (19).] Similar
calculations for x = 1 mg/kg/day give
p*(0.93) = 0.000015 for the Michaelis-
Menten model [or p*(1) - 0.000019 for
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the PBPK model] compared to p*(1) =
0.0016 for the administered dose model,
i.e., at an administered dose level of 1
mg/kg, risk estimated from the internal
dose model is about 1% of the risk esti-
mated from the administered dose model.
At lower doses (corresponding to inhalation
doses below 1 ppm) the cubic internal dose
model gives lifetime cancer risk predictions
less than 1% as large as those from the
linear-quadratic administered dose model.
There are several reasons to believe that
the cubic internal dose-response risk model
may be more realistic than the adminis-
tered dose-response model. If a Weibull
model ofthe form p(y) = 1 -exp[-(a+ byc)]
is fit to the four internal dose response
points in Table 4, the result is the MLE
Weibull risk model
(plly) = 1 -exp(-0.0000015y3.065).
Thus, the conclusion that the relation
between internal dose and probability of
response is approximately cubic (rather
than linear or quadratic) does not appear
to be only an artifact of using the multi-
stage family ofrisk models. Also, the inter-
nal dose risk model provides a slightly
better fit than the administered dose risk
model to the available animal dose-
response data. The sample values of (pII x)
at x = 25, 50, and 100 mg/kg/day are
(plIx) = 0.08, 0.40, and 0.74. The corre-
sponding values predicted by the adminis-
tered dose linear-quadratic model are 0.11,
0.33, and 0.77, while the values predicted
by the cubic model with the Michaelis-
Menten internal dose model are 0.105,
0.37, and 0.755. In each case, the best-
fitting (cubic) internal dose-response
model predicts values of (p II x) slightly
closer to the observed ones than the corre-
sponding predictions from the best fitting
(linear-quadratic) administered dose-
response model. Quantitatively, the inter-
nal dose model provides a better fit to the
data, with the maximized value ofthe log-
likelihood function being -76.53 for the
internal dose model compared to -77.15
for the administered dose model. Finally,
the internal dose-response model appears
to be much more consistent with epi-
demiological data on tumors in heavily
benzene-exposed workers (Turkish shoe
workers and Chinese workers) than the
administered dose-response model.
For an administered dose of x = 1
mg/kg/day, the internal dose model
predicts an MLE risk ofonly 0.0000155,
which is about 1% as large as the MLE risk
predicted by the administered dose model.
On the other hand, the respective upper
UCLs for risk at x= 1 mg/kg/day are 0.005
for the internal dose model compared to
0.008 for the administered dose model.
Thus, even though the MLE estimates dif-
fer by a factor of 100, the 95% UCLs
based on traditional qi* uncertainty analy-
sis are very similar. This insensitivity of
95% UCLs to significant variations in risk
models is typical; it has been both criti-
cized as a defect and praised as a virtue of
the qj* approach.
BiologicailyBased
RiskAssessmentModeling
Biologically based computer simulation
models are available for quantifying some
of the key microrelations thought to be
involved in benzene leukemia causation,
including (yII x) and (Nl x). Where such
models exist, they can be used to quantify
the output histories, like {y} and {N},
caused by any benzene administered dose
history, {x}. Instead of using dose metrics
for risk extrapolation, therefore, it is
possible to construct explicit computer
simulation models ofthe pharmacokinetic
and pharmacodynamic processes (ideally
including hematotoxicity and genotoxicity)
mediating between benzene exposure and
AML induction.
Such biologically based risk assessment
(BBRA) models have the advantage ofmak-
ing explicit, testable predictions ofobserv-
able quantities (such as quantities of
benzene metabolites formed, cell population
sizes, and so forth) as well as tumor risk,
which is much harder to observe directly.
They also bypass the need to rely upon dose
metrics, which may not exist in any useful
form for benzene. On the other hand,
BBRA models are often too complex and
detailed and require too many uncertain
inputs to be used for regulatory risk assess-
ment and public health risk management.
A principle expoited in this article to
avoid complexity is that if administered
dose histories are restricted to simple
forms, then the full dynamic simulation
approach becomes unnecessary. Specifi-
cally, under a wide range ofconditions, a
constant administered dose eventually
produces a constant steady-state output for
each component of {y} and {N}. In this
case, letting x denote the constant applied
concentration (in ppm, for inhalation
exposures) and letting y(x) and N(x)
denote the resulting steady-state levels ofa
specified benzene metabolite and cell pop-
ulation, respectively, it is possible to quan-
tify the relations (yII x) and (Nllx) using
nonlinear regression models such as
y(x)= Vx/(K+x)
(Michaelis-Menten nonlinear
regression model)
where Vand Kare model parameters to be
estimated from observed data (such as
[x,y] pairs, in this example). Alternatively,
ifa PBPK model is available, as is the case
for benzene, it can be used to quantify
many (x, y) pairs, and then a relatively
simple nonlinear regression model can be
used to describe the results, bypassing the
need to use the PBPK model itselfwhen
only simple, constant dose scenarios are
being considered.
Conclusion
The conclusions ofgreatest potential prac-
tical interest from the preceding analyses
are as follows. a) There is no evidence ofa
positive relation between benzene exposure
and tumor probability (or causal antece-
dents such as depressed myeloid stem cell
and HPC populations) at benzene concen-
trations below 1 ppm. b) Different analytic
approaches-including Bayesian Monte-
Carlo uncertainty analysis and PBPK-based
internal dose modeling-suggest that the
(p1 x) curve relating benzene concentra-
tion to AML risk at sufficiently low, con-
stant concentrations ofbenzene approaches
a zero or negative slope as concentration
falls below about 10 ppm. c) Empirical
data and biologically based risk models
agree that, for the same total administered
dose (AUC), higher concentrations ofben-
zene may cause disproportionately large
hematotoxic responses.
Quantitatively, none ofthe statistical or
biological evidence investigated suggests
that reducing benzene concentrations
below 1 ppm would have any detectable
health benefits. The hypothesis ofa zero or
nonpositive slope for excess risks due to
inhalation oflow concentrations of ben-
zene may have sufficiently interesting
public health policy implications to merit
further evaluation.
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Appendix: Benzene
Hematotoxicity Model Equations
and Parameter Values
HPC Cells
d (cycling_HPCs)/dt = recruited_from_resting + (cell_divisions -
HPC_deaths) - return_to_resting - differentiated
d(resting_HPCs)/dt = return_to_resting - recruited_from_resting
recruited_from_resting = HPC_recruitment_rate *
resting_HPCs
cell_divisions = recruited_from_resting {since each recruited
cell divides at mitosis}
HPC_deaths = cyclingHPCs * cytotoxic_potency_for_HPCs
* metabolite_in_cells
metabolite_in_cells = output from PK model
return_to_resting = (1 -HPC_differentiation_fraction) *
cycling_HPCs / HPC_cycle_time
differentiated = HPC_differentiation_fraction * cyclingHPCs/
HPC_ycle_time
CFU-GM Cells
dCFU(1, t)ldt = differentiated -[CFU(1,t)/CFU_transit_time] -
(CFU_death_rate - CFU_birth_rate) * CFU(1, t)
dCFU(i, t)ldt = [CFU(i- 1, t)/CFU_transit_time]
[CFU(i,t)/CFU_transit_time] -(CFU_death_rate - CFU_birth_
rate) * CFU(i, t), for i= 2,3, ..., 10
GM Proliferation
dP(1,t) = inflow_from_CFU_GM(t) - [P(1,t)/IP_transit-time] -
(P_death_rate -P_birth rate) * P(1,t)
dP(i,t) = [P(i - 1,t)/P transit_time] - [P(i,t)I/P transit-time] -
(P_death_rate - P_birth rate) * P(i, t), for i = 2, 3, ..., 10
inflow_from_CFU-GM(t) = G(10, t)/CFU_transit_time
P_death_rate = cytotoxicity-potency-forproliferatingcells *
metabolite_in_cells
Nonproliferative Populations
dMIdt = precursors_in - matured_cells_out
precursors_in = matured_cells_out(t) = M(t)/maturation_tran-
sit_time
dRNdt = matured_cells_out - release_rate_to_blood * R
dBldt = release_rate_to_blood * R -decay-rate*B
HPC_recruitment_rate =
kl * EXP(-vl * resting_HPCs - vl * cycling_HPCs) + k2 *
EXP(-v2 * Z) + k3
kl = 0.36{per hr}
k3 = 0.008 {per hr}
vl = 1.6955E-6
k2 = 0.04 {per hr}
v2 = 3.1918E-ll
Z= (signal_Z+ CFU_GM) {=3.208E9 + 3.469E10 +
12.8E10 in steadystatel
signalZ = proliferating-pool + maturation-pool + mar-
row_reserve = P+ M+ R
HPC_differentiation_fraction =
1 - MAX(0, 0.5 + 1.76E-9 * (steady_state_HPCs - rest-
ing_HPCs - cycling_HPCs))
steady_state_HPCs = 3.125E8 {HPC cells in steadystatel
CFU_birth_rate = 0.1/(3 + min(0.2, k4 * resting_HPCs + k4 *
cycling_HPCs) + min(0.2, k5 * CFU_GM) + min(0.2, k6 *
signal_Z))
k4 = 3.6418E-9 k5 = 3.5476E-10
k6 = 6.9953E-12
(22, calculated from steady-state conditions)
CFU_GM = CFU_GM_1 + CFU_GM_2 + CFU_GM_3 +
CFU_GM_4 + CFU_GM_5 + CFU_GM_6 +
CFU_GM_7 + CFU_GM_8 + CFU_GM_9 +
CFU_GM_10
CFU_transit_time = 10 {hr for each of 10 compartments =
100 hr}
CFU_GM_cytotoxicity_death_rate = metabolite_in_cells *
cytotoxicpotency_for_CFU_GM
cytotoxic_potency_for_CFU_GM = 0.13 {per proliferating
cell/hr}
P_birth rate = 0.07/(1 + min(0.6, k7*Z)) (19, eq. [16])
k7 = 3.7289666E-12; Z= (signal_Z+ CFU_GM)
P transit_time = 5.6 {hrforeach of 10 compartments = 56 hr}
cytotoxicpotencyjor_proliferating cells = 0.13 {perprolifer-
ating cell/hr}
P= proliferating-pool = P1 + P2 + P3 + P4 + P5 + P6 + P7
+ P8 + P9 + PIO
P_death_rate = cytotoxicty_death rate_for_proliferating_cells =
metabolite_in_cells * cytotoxic_potency-for_proliferating
cytotoxicpotency_forproliferating = 0.13 {per prolifer-
ating cell/hr}
release_rate_to_blood = k8 - k9 * EXP(-v3 * GRF) = 2 -
1.9875 * EXP(-6.309E-4 * GRF)
blood_decay_rate = 0.1 (22)
GRF_decay_rate = 0.1 {per hr (22)}
Environmental Health Perspectives * Vol 104, Supplement 6 * December 1996 1428REASSESSING BENZENE RISKS
REFERENCES
1. Spear RC, Bois FY, WoodruffT, Asslander D, Parker J, Selvin
S. Modeling benzene pharmacokinetics across three sets ofani-
mal data: parametric sensitivity and risk implications. RiskAnal
11:641-654 (1991).
2. Crump KS, Allen BC. Quantitative Estimates of the Risk of
Leukemia from Occupational Exposures to Benzene. Final
Report to the Occupational Safety and Health Administration.
Ruston, LA:Science Research Systems, 1984.
3. Occupational Safety and Health Administration (OSHA). 29
CFR Part 1910. Occupational Exposure to Benzene: Final
Rule. Fed Reg September 11, 1987, 34,460-34,508.
4. U.S. EPA. Interim Quantitative Cancer Unit Risk Estimates
Due to Inhalation of Benzene. EPA-600/X-85-022.
Washington:U.S. Environmental Protection Agency, 1985.
5. Lawless JF. Statistical Models and Methods for Lifetime Data.
NewYork:John Wiley & Sons, 1981.
6. Bailer AJ, Hoel DG. Metabolite-based internal doses used in a
risk assessment of benzene. Environ Health Perspect
82:177-184, 1989.
7. Green JD, Snyder CA, LoBue J, Goldstein BD, Albert RE.
Acute and chronic dose/response effect ofbenzene inhalation
on the peripheral blood, bone marrow, and spleen cells ofCD-
1 male mice. Toxicol Appl Pharmacol 59:204214 (1981).
8. Toft K, Olofsson T, Tunek A, Berlin M. Toxic effects of
mouse bone marrow caused by inhalation of benzene. Arch
Toxicol 51:295-302 (1982).
9. Luke CA, Tice RR, Drew RT. The effects ofexposure regimen
and duration on benzene-induced bone marrow damage in mice.
I: Sex comparison on DBA/2 mice. Mutat Res 203:251-272
(1988).
10. Portier C, Hoel D. Low-dose extrapolation using the multi-
stage model. Biometrics 39:341-352 (1983).
11. Cox LAJr. An exact analysis ofthe multistage model explaining
dose-response concavity. RiskAnal 15(3):359-368 (1995).
12. Hjorth JS. Urban. Computer Intensive Statistical Methods:
Validation, Model Selection, and Bootstrap. New
York:Chapman and Hall, 1994.
13. Aksoy M. Hematotoxicity and carcinogenicity of benzene.
Environ Health Perspect 82:193-197 (1989).
14. Tarter ME, Lock MD. Model-Free Curve Estimation. New
York:Chapman and Hall, 1993.
15. Jessop A. Informed Assessments: An Introduction to Information,
Entropy, and Statistics. NewYork:Ellis Horwood, 1995.
16. DeGroot MH. Probability and Statistics. New York:Addison
Wesley 1975;266-268.
17. Travis C, Quillen JL, Arms AD. Pharmacokinetics ofbenzene.
Toxicol Appl Pharmacol 102:400-420 (1990).
18. Medinsky M, Sabourin PJ, Lucier G, Birnbaum LS, Henderson
RF. A physiological model forsimulation ofbenzene metabolism
by rats and mice. Toxicol AppI Pharmacol 99:193-206 (1989).
19. Henderson RF, Sabourin PJ, Bechtold WE, Griffith WC,
Medinsky MA, Birnbaum LS, Lucier GW. The effect of dose,
dose rate, route ofadministration, and species on tissue and
blood levels ofbenzene metabolites. Environ Health Perspect
82:9-17 (1989).
20. Cox LA Jr, Ricci PF. Reassessing benzene cancer risks using
internal doses. RiskAnaly 12(3):401-410 (1992).
21. Scheding S, Loeffler M, Schmitz S, Seidel HJ, Wichmann HE.
Hematotoxic effects of benzene analyzed by mathematical
modeling. Toxicology 72:265-279 (1992).
22. SteinbachKH, Raffler H, Pabst G, Fliedner TM. A mathematical
model ofcanine granulocytopoiesis. J Math Biol 10:1-12 (1981).
23. Quiggin J. Generalized Expected Utility Theory: The Rank-
Dependent Model. Boston:KluwerAcademic Publishers, 1993.
Environmental Health Perspectives * Vol 104, Supplement 6 * December 1996 1429